about
Potential biomarkers for esophageal cancerHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsPredictive and prognostic molecular markers for cancer medicineRisk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.Detection of SYT and EWS gene rearrangements by dual-color break-apart CISH in liquid-based cytology samples of synovial sarcoma and Ewing sarcoma/primitive neuroectodermal tumor.Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationTesting for HER2 in Breast Cancer: A Continuing Evolution.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancerSISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.HER2 expression in gastric and oesophageal cancer: a meta-analytic reviewHER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein arrayHuman epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slideThe clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray.HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.Genetically informed lung cancer medicine.Added value of molecular targeted agents in oncology.Update on HER2 testing for breast and upper gastrointestinal tract cancers.The human epidermal growth factor receptor 2 (HER2).Triple-negative breast cancer: making the most of a misnomer.Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma.Advances in biomarkers for esophageal cancer.HER2 assessment by silver in situ hybridization: where are we now?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.The vanguard has arrived in the clinical laboratory: array-based karyotyping for prognostic markers in chronic lymphocytic leukemia.Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition.Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study.Aberrant expression and altered cellular localization of desmosomal and hemidesmosomal proteins are associated with aggressive clinicopathological features of oral squamous cell carcinoma.
P2860
Q26749416-D67C8E8D-DDB5-4748-9E6E-15B3FB86F810Q26822730-A2A06033-8980-4EE8-B4CA-C52D3A34B79BQ28077666-CAE70A51-DDB0-458A-AB04-4900C165D3CFQ28078111-6B5A677F-3537-40EA-8A60-F1C8C49E067CQ28743108-765949F3-EAB7-4E09-ADEF-750FDD727674Q30541773-DC3582DE-EEFE-40A2-AFF1-130D7AEBD572Q33641011-99A2B230-12C2-42F9-86F2-CABCE3B786A1Q34084063-A9BAB28F-1365-4DA5-8CB8-5351ACF87F50Q34424285-8165B61C-265B-438F-B943-CB5614E6F357Q34638138-D77EAA89-C6D1-415F-ACB1-2C2973F95243Q34855870-85BA1A6C-8089-43B0-986C-C456B2D805B8Q35029025-0898DE7A-8EBC-4FE3-A8C8-F59B1D00E0B8Q35184966-CAA10AA6-ED4A-4DEB-8B05-75CFD47B2290Q35670454-6F13F85B-D650-46C5-9C6D-88122B48109CQ35929360-398D211D-D731-49B1-8CB9-600DF0E7D697Q36761689-2C3E5728-B20D-4283-BDC4-D14084151ABCQ37392419-BE1ED66B-0122-48D2-912B-F48E0F0EF798Q37582166-E14932D7-0E07-49B2-81FF-1775E542EC7FQ37815136-C53CDCF4-F2E0-4F25-91E4-73F1AB09DBC9Q37837267-980406D4-502C-4B7D-8279-D2DF5E03EE2EQ37886993-90B87EE3-99B0-4633-96C1-94857DCD0C57Q37932507-C000E33B-27F1-4AAF-A064-A664CB36866DQ38004606-E857DDC6-B54C-426E-8B93-B068230A6E6BQ38046575-6DDFE4D8-49C5-41EE-BB7C-64E6F77ACB7FQ38072066-186F8B00-52AA-4B1F-90C8-552867F95B55Q38153443-5442947F-D401-427C-AEB2-22C38C74CE4EQ38314355-E555C80D-B7CA-4538-9FD4-80CD065D9B09Q38326102-43A6BC87-0A47-4A3F-A038-0BE5E2F3ADC9Q38412375-0BF8E417-4E48-406D-9CF5-F75B6CA31923Q38612634-7AFB6F78-C267-4A1C-9D18-F81EC949E1B7Q38618238-52907F57-901D-46AE-A44E-59F29B845DDAQ40609808-CA295ADF-84B7-461F-9CF3-C034740B0075Q40748887-61059DCC-647E-4B4C-9305-B2FF9D68FAA4Q40777892-746D0200-EB55-48DC-A742-F5C3F4067D23Q42282776-6BD6A7F7-500F-44AA-88EC-6A045B66952EQ45782977-A45D5C2A-2AB3-4931-BD73-6F5FBF7CF201Q46565660-5499F286-5919-4ADA-8C2D-66690DFD3124Q47254055-2CD3744D-CAA7-4C4D-9922-346C3A82FC33Q50878559-74595E3D-2EDE-45EE-B9E7-35723BF53132Q52650399-91EBD1A2-AA1E-45B7-B419-55B37713FBA4
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Emerging technologies for assessing HER2 amplification.
@ast
Emerging technologies for assessing HER2 amplification.
@en
Emerging technologies for assessing HER2 amplification.
@nl
type
label
Emerging technologies for assessing HER2 amplification.
@ast
Emerging technologies for assessing HER2 amplification.
@en
Emerging technologies for assessing HER2 amplification.
@nl
prefLabel
Emerging technologies for assessing HER2 amplification.
@ast
Emerging technologies for assessing HER2 amplification.
@en
Emerging technologies for assessing HER2 amplification.
@nl
P2093
P50
P356
P1476
Emerging technologies for assessing HER2 amplification.
@en
P2093
Josef Rüschoff
Michael Bilous
Robert Yoshiyuki Osamura
Wedad Hanna
P304
P356
10.1309/AJCPV2I0HGPMGBSQ
P407
P577
2009-10-01T00:00:00Z